Acyl CoA:diacylglycerol acyltransferase (DGAT) 1 catalyzes the final step of
triglyceride (TG) synthesis. We show that acute administration of a DGAT1 inhibitor
(DGAT1i) by oral gavage or genetic deletion of intestinal Dgat1
(intestine-Dgat1−/−)
markedly reduced postprandial plasma TG and retinyl ester excursions by inhibiting
chylomicron secretion in mice. Loss of DGAT1 activity did not affect the efficiency
of retinol esterification, but it did reduce TG and retinoid accumulation in the
small intestine. In contrast, inhibition of microsomal triglyceride transfer protein
(MTP) reduced chylomicron secretion after oral fat/retinol loads, but with
accumulation of dietary TG and retinoids in the small intestine. Lack of intestinal
accumulation of TG and retinoids in DGAT1i-treated or
intestine-Dgat1−/− mice
resulted, in part, from delayed gastric emptying associated with increased plasma
levels of glucagon-like peptide (GLP)-1. However, neither bypassing the stomach
through duodenal oil injection nor inhibiting the receptor for GLP-1 normalized
postprandial TG or retinyl esters excursions in the absence of DGAT1 activity. In
summary, intestinal DGAT1 inhibition or deficiency acutely delayed gastric emptying
and inhibited chylomicron secretion; however, the latter occurred when gastric
emptying was normal or when lipid was administered directly into the small intestine.
Long-term hepatic retinoid metabolism was not impacted by DGAT1 inhibition.
Retinoids (vitamin A and its analogs) are highly potent regulators of cell differentiation, cell proliferation, and apoptosis. Because of these activities, retinoids have been most extensively studied in the contexts of embryonic development and of proliferative diseases, especially cancer and skin disease. Recently, there has been considerable new research interest focused on gaining understanding of the roles that retinoids and/or retinoid-related proteins may have in the development of metabolic diseases, primarily obesity, diabetes, and dyslipidemia. This review will summarize recent advances that have been made in these areas, focusing on the role of retinoids in modulating adipogenesis, the roles of retinoids and retinoid-related proteins as signaling molecules linking obesity with the development of type II diabetes, the roles of retinoids in pancreatic β-cell biology/insulin secretion, and the actions of retinoids in hepatic steatosis.
Expressed in the small intestine, retinol-binding protein 2 (RBP2) facilitates dietary retinoid absorption. Rbp2-deficient (Rbp2−/−) mice fed a chow diet exhibit by 6-7 months-of-age higher body weights, impaired glucose metabolism, and greater hepatic triglyceride levels compared to controls. These phenotypes are also observed when young Rbp2−/− mice are fed a high fat diet. Retinoids do not account for the phenotypes. Rather, RBP2 is a previously unidentified monoacylglycerol (MAG)-binding protein, interacting with the endocannabinoid 2-arachidonoylglycerol (2-AG) and other MAGs with affinities comparable to retinol. X-ray crystallographic studies show that MAGs bind in the retinol binding pocket. When challenged with an oil gavage, Rbp2−/− mice show elevated mucosal levels of 2-MAGs. This is accompanied by significantly elevated blood levels of the gut hormone GIP (glucose-dependent insulinotropic polypeptide). Thus, RBP2, in addition to facilitating dietary retinoid absorption, modulates MAG metabolism and likely signaling, playing a heretofore unknown role in systemic energy balance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.